Prevalence of hepatitis B and C viruses among migrant workers in Qatar.
Humans
Qatar
/ epidemiology
Hepatitis B
/ epidemiology
Female
Transients and Migrants
/ statistics & numerical data
Hepatitis C
/ epidemiology
Adult
Male
Prevalence
Cross-Sectional Studies
Middle Aged
Hepacivirus
/ immunology
Hepatitis B virus
/ isolation & purification
Young Adult
COVID-19
/ epidemiology
Adolescent
Hepatitis B Surface Antigens
/ blood
Hepatitis C Antibodies
/ blood
Cross-sectional
HBV
HCV
Hepatitis
Infection
Prevalence
Qatar
Workers
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
received:
15
02
2024
accepted:
08
05
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
epublish
Résumé
Limited data exist on viral hepatitis among migrant populations. This study investigated the prevalence of current hepatitis B virus (HBV) infection and lifetime hepatitis C virus (HCV) infection among Qatar's migrant craft and manual workers (CMWs), constituting 60% of the country's population. Sera collected during a nationwide COVID-19 population-based cross-sectional survey on CMWs between July 26 and September 9, 2020, underwent testing for HBsAg and HCV antibodies. Reactive samples underwent confirmatory testing, and logistic regression analyses were employed to explore associations with HBV and HCV infections. Among 2528 specimens tested for HBV infection, 15 were reactive, with 8 subsequently confirmed positive. Three samples lacked sufficient sera for confirmatory testing but were included in the analysis through multiple imputations. Prevalence of current HBV infection was 0.4% (95% CI 0.2-0.7%). Educational attainment and occupation were significantly associated with current HBV infection. For HCV infection, out of 2607 specimens tested, 46 were reactive, and 23 were subsequently confirmed positive. Prevalence of lifetime HCV infection was 0.8% (95% CI 0.5-1.2%). Egyptians exhibited the highest prevalence at 6.5% (95% CI 3.1-13.1%), followed by Pakistanis at 3.1% (95% CI 1.1-8.0%). Nationality, geographic location, and occupation were significantly associated with lifetime HCV infection. HBV infection is relatively low among CMWs, while HCV infection falls within the intermediate range, both compared to global and regional levels.
Identifiants
pubmed: 38760415
doi: 10.1038/s41598-024-61725-9
pii: 10.1038/s41598-024-61725-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11275Subventions
Organisme : Qatar Research, Development and Innovation (QRDI) Council
ID : UREP30-041-3-014
Organisme : Qatar National Research Fund
ID : NPRP grant number 12S-0216-190094
Organisme : Weill Cornell Medicine - Qatar
ID : Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core
Organisme : Qatar University
ID : QUCG-CAS-23/24-114
Informations de copyright
© 2024. The Author(s).
Références
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G. & Ott, J. J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 386, 1546–1555. https://doi.org/10.1016/S0140-6736(15)61412-X (2015).
doi: 10.1016/S0140-6736(15)61412-X
pubmed: 26231459
Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088. https://doi.org/10.1016/S0140-6736(16)30579-7 (2016).
doi: 10.1016/S0140-6736(16)30579-7
pubmed: 27394647
pmcid: 5100695
Hsu, Y.-C., Huang, D. Q. & Nguyen, M. H. Global burden of hepatitis B virus: Current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 20, 524–537. https://doi.org/10.1038/s41575-023-00760-9 (2023).
doi: 10.1038/s41575-023-00760-9
pubmed: 37024566
Maheshwari, A., Ray, S. & Thuluvath, P. J. Acute hepatitis C. Lancet 372, 321–332 (2008).
doi: 10.1016/S0140-6736(08)61116-2
pubmed: 18657711
Lauer, G. M. & Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 345, 41–52 (2001).
doi: 10.1056/NEJM200107053450107
pubmed: 11439948
World Health Organization. Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022–2030. file:///C:/Users/gm15/Downloads/9789240053779-eng.pdf. Accessed 7 June 2023 (2022).
World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections 2021. https://www.who.int/publications/i/item/9789240027077 . Accessed 4 Dec 2023. (World Health Organization, 2021).
World Health Organization. Epidemiology of Hepatitis C Virus in the WHO Eastern Mediterranean Region: Implications for Strategic Action. https://applications.emro.who.int/docs/9789290222866-eng.pdf?ua=1 . Accessed 5 Dec 2023 (WHO Regional Office for the Eastern Mediterranean, 2020).
Vermehren, J., Park, J. S., Jacobson, I. M. & Zeuzem, S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J. Hepatol. 69, 1178–1187 (2018).
doi: 10.1016/j.jhep.2018.07.002
pubmed: 30006068
Horsley-Silva, J. L. & Vargas, H. E. New therapies for hepatitis C virus infection. Gastroenterol. Hepatol. 13, 22 (2017).
El-Akel, W. et al. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J. Viral Hepat. 24, 262–267. https://doi.org/10.1111/jvh.12668 (2017).
doi: 10.1111/jvh.12668
pubmed: 28145032
Flamm, S. L. Advances in the treatment of hepatitis C virus infection from EASL 2015. Gastroenterol. Hepatol. 11, 1–23 (2015).
Ayoub, H. H. & Abu-Raddad, L. J. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. J. Viral Hepat. 24, 486–495. https://doi.org/10.1111/jvh.12671 (2017).
doi: 10.1111/jvh.12671
pubmed: 28039923
Chevaliez, S. Strategies for the improvement of HCV testing and diagnosis. Expert Rev. Anti Infect. Ther. 17, 341–347. https://doi.org/10.1080/14787210.2019.1604221 (2019).
doi: 10.1080/14787210.2019.1604221
pubmed: 30950298
Abu-Raddad, L. J. et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci. Rep. 11, 6233. https://doi.org/10.1038/s41598-021-85428-7 (2021).
doi: 10.1038/s41598-021-85428-7
pubmed: 33737535
pmcid: 7973743
Al-Thani, M. H. et al. SARS-CoV-2 infection is at Herd immunity in the majority segment of the population of Qatar. Open Forum Infect. Dis. 8, 221. https://doi.org/10.1093/ofid/ofab221 (2021).
doi: 10.1093/ofid/ofab221
Al Nuaimi, A. A. et al. All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic. BMJ Glob. Health https://doi.org/10.1136/bmjgh-2023-012291 (2023).
doi: 10.1136/bmjgh-2023-012291
pubmed: 37142299
Nasrallah, G. K. et al. Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar. Virol. J. 20, 188. https://doi.org/10.1186/s12985-023-02157-1 (2023).
doi: 10.1186/s12985-023-02157-1
pubmed: 37608372
pmcid: 10463979
Younes, N. et al. Seroprevalence of hepatitis E virus (HEV) among male craft and manual workers in Qatar (2020–2021). Heliyon 9, e21404. https://doi.org/10.1016/j.heliyon.2023.e21404 (2023).
doi: 10.1016/j.heliyon.2023.e21404
pubmed: 38027884
pmcid: 10660033
Jeremijenko, A. et al. Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar. Emerg. Infect. Dis. 27, 1343–1352. https://doi.org/10.3201/eid2705.204365 (2021).
doi: 10.3201/eid2705.204365
pubmed: 33900174
pmcid: 8084480
Ministry of Interior-State of Qatar. Population Distribution by Sex, Age, and Nationality: Results of Kashef Database (2020).
Planning and Statistics Authority-State of Qatar. Labor Force Sample Survey. https://www.psa.gov.qa/en/statistics/Statistical%20Releases/Social/LaborForce/2017/statistical_analysis_labor_force_2017_En.pdf . Accessed 23 May 2022 (2017).
World Health Organization. Population-Based Age-Stratified Seroepidemiological Investigation Protocol for COVID-19 Virus Infection. https://apps.who.int/iris/handle/10665/331656 . Accessed 15 Apr 2020 (2020).
Mindray. Mindray HBsAg CL-900i Chemiluminescence Immunoassay Analyzer. Cat. No. HBsAg112, Shenzhen, China (2015).
Pasaribu, M. M. et al. Cutoff value of qualitative HBsAg for confirmatory HBsAg using the chemiluminescence microparticle immunoassay method. Lab. Med. 53, 475–478. https://doi.org/10.1093/labmed/lmac021 (2022).
doi: 10.1093/labmed/lmac021
pubmed: 35394549
Abbott. ARCHITECT HBsAg Qualitative II Confirmatory assay. Abbott Ireland, Sligo, Ireland (2020).
Mindray. Mindray CL-900i Chemiluminescence Immunoassay Analyzer. Cat. No. HCV112, Shenzhen, China (2015).
AB Diagnostic Systems. Abia HCV Ab Enzyme-Linked Immunosorbent Assay (ELISA). Cat. No: DK.067.01.3, Berlin, Germany. file:///C:/Users/hsc2001/Downloads/DK067013.pdf. Accessed 21 Nov 2023 (2021).
Fujirebio. Fujirebio INNO-LIA HCV Score Line Immunoassay. 80538 INNO-LIA HCV Score / 28667 v6 / KEY-CODE: FRI32604, Tokyo, Japan. https://search.cosmobio.co.jp/cosmo_search_p/search_gate2/docs/IGT_/80538.20170308.pdf . Accessed 21 Nov 2023. (2016).
Fleiss, J. L., Levin, B. & Paik, M. C. Statistical Methods for Rates and Proportions. 598–626 (Wiley, 2013).
Aldisi, R. S. et al. Performance evaluation of four type-specific commercial assays for detection of herpes simplex virus type 1 antibodies in a Middle East and North Africa population. J. Clin. Virol. 103, 1–7. https://doi.org/10.1016/j.jcv.2018.03.011 (2018).
doi: 10.1016/j.jcv.2018.03.011
pubmed: 29597097
Ott, J. J., Horn, J., Krause, G. & Mikolajczyk, R. T. Time trends of chronic HBV infection over prior decades—A global analysis. J. Hepatol. 66, 48–54. https://doi.org/10.1016/j.jhep.2016.08.013 (2017).
doi: 10.1016/j.jhep.2016.08.013
pubmed: 27592304
Ginzberg, D., Wong, R. J. & Gish, R. Global HBV burden: Guesstimates and facts. Hepatol. Int. 12, 315–329. https://doi.org/10.1007/s12072-018-9884-8 (2018).
doi: 10.1007/s12072-018-9884-8
pubmed: 30054801
World Health Organization. Global Status Report on Blood Safety and Availability 2016. Report No.: 9789241565431. https://apps.who.int/iris/bitstream/handle/10665/254987/9789241565431-eng.pdf . Accessed 12 Jan 2021 (2021).
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333–1342. https://doi.org/10.1002/hep.26141 (2013).
doi: 10.1002/hep.26141
pubmed: 23172780
Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17, 107–115 (2011).
doi: 10.1111/j.1469-0691.2010.03432.x
pubmed: 21091831
Chemaitelly, H., Mahmud, S., Rahmani, A. M. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Afghanistan: Systematic review and meta-analysis. Int. J. Infect. Dis. 40, 54–63 (2015).
doi: 10.1016/j.ijid.2015.09.011
pubmed: 26417880
Mohamoud, Y. A., Riome, S. & Abu-Raddad, L. J. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int. J. Infect. Dis. 46, 116–125 (2016).
doi: 10.1016/j.ijid.2016.03.012
pubmed: 26996460
Chemaitelly, H., Chaabna, K. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in the fertile crescent: Systematic review and meta-analysis. PLOS ONE 10, e0135281 (2015).
doi: 10.1371/journal.pone.0135281
pubmed: 26296200
pmcid: 4546629
Fadlalla, F. A., Mohamoud, Y. A., Mumtaz, G. R. & Abu-Raddad, L. J. The Epidemiology of hepatitis C virus in the Maghreb Region: Systematic review and meta-analyses. PloS one 10, e0121873 (2015).
doi: 10.1371/journal.pone.0121873
pubmed: 25803848
pmcid: 4372394
Chaabna, K., Kouyoumjian, S. P. & Abu-Raddad, L. J. Hepatitis C virus epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic review and meta-analysis. PloS one 11, e0149966 (2016).
doi: 10.1371/journal.pone.0149966
pubmed: 26900839
pmcid: 4764686
Mahmud, S., Akbarzadeh, V. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci. Rep. 8, 150. https://doi.org/10.1038/s41598-017-18296-9 (2018).
doi: 10.1038/s41598-017-18296-9
pubmed: 29317673
pmcid: 5760657
Ayoub, H. H., Chemaitelly, H., Kouyoumjian, S. P. & Abu-Raddad, L. J. Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt. Int. J. Epidemiol. 49, 798–809. https://doi.org/10.1093/ije/dyaa052 (2020).
doi: 10.1093/ije/dyaa052
pubmed: 32357208
pmcid: 7394952
Kouyoumjian, S. P., Chemaitelly, H. & Abu-Raddad, L. J. Characterizing hepatitis C virus epidemiology in Egypt: Systematic reviews, meta-analyses, and meta-regressions. Sci. Rep. 8, 1661. https://doi.org/10.1038/s41598-017-17936-4 (2018).
doi: 10.1038/s41598-017-17936-4
pubmed: 29374178
pmcid: 5785953
Mohamoud, Y. A., Mumtaz, G. R., Riome, S., Miller, D. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Egypt: A systematic review and data synthesis. BMC Infect. Dis. 13, 288. https://doi.org/10.1186/1471-2334-13-288 (2013).
doi: 10.1186/1471-2334-13-288
pubmed: 23799878
pmcid: 3702438
Al Kanaani, Z., Mahmud, S., Kouyoumjian, S. P. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Pakistan: Systematic review and meta-analyses. R. Soc. Open Sci. 5, 180257. https://doi.org/10.1098/rsos.180257 (2018).
doi: 10.1098/rsos.180257
pubmed: 29765698
pmcid: 5936963
Ayoub, H. H., Al Kanaani, Z. & Abu-Raddad, L. J. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. J. Viral Hepat. 25, 670–679. https://doi.org/10.1111/jvh.12864 (2018).
doi: 10.1111/jvh.12864
pubmed: 29345847
Mahmud, S., Al Kanaani, Z. & Abu-Raddad, L. J. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect. Dis. 19, 809. https://doi.org/10.1186/s12879-019-4403-7 (2019).
doi: 10.1186/s12879-019-4403-7
pubmed: 31521121
pmcid: 6744714
Goel, A., Rewari, B. B., Sharma, M., Konath, N. M. & Aggarwal, R. Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review. J. Gastroenterol. Hepatol. 37, 964–972. https://doi.org/10.1111/jgh.15827 (2022).
doi: 10.1111/jgh.15827
pubmed: 35263807